Introduction
============

Keratoconus (KC) is a noninflammatory progressive thinning disorder of the cornea that leads to progressive mixed myopic and irregular astigmatism \[[@r1]\]. The estimated incidence of KC is between 1 in 500 and 1 in 2,000 in the general population \[[@r1]\]. KC occurs in all ethnic groups, with no significant gender difference. The age of onset is puberty, and KC is progressive until the third to fourth decade of life when it usually arrests. It is the major cause of cornea transplantation in developed countries. Although the cause of KC is unknown, there are several lines of evidence suggesting a genetic component. These include a positive family history in 6--10% of KC cases \[[@r1],[@r2]\] and its higher concordance rate in monozygotic twins \[[@r1],[@r3]\]. Although the disease has been reported to exhibit familiar patterns and an autosomal recessive mode of inheritance has been postulated, most cases appear to be sporadic \[[@r4],[@r5]\] Hereditary KC is inherited dominantly or recessively, but families are frequently diagnosed with autosomal dominant, which presents incomplete penetrance of the disease and variable expressivity \[[@r5]\]. The underlying biochemical processes and their cause remain poorly understood. By far the most common presentation of KC is as an isolated sporadic disorder, but a positive association between KC and many conditions has been suggested, including atopy, eye rubbing, wearing hard contact lens, and cardiovascular disease (especially mitral valve prolapse) as well as some rare genetic disorders, connective tissue disorders, pigmentary retinopathy, Marfan's syndrome, Noonan's syndrome, Apert's syndrome, Ehlers-Danlos syndrome, and Down syndrome \[[@r1],[@r6]\].

The major protein in the cornea is collagen, and several types of collagen have been identified by biochemical and immunochemical methods \[[@r7]\]. Corneas from patients with KC contain reduced amounts of total collagen proteins, \[[@r8]\] and alterations of the extra cellular matrix and basement membrane are characterized mostly by a decrease in types I and III \[[@r9]\]. The changes in the orientation of collagen molecules, which are followed by rearrangement of collagen fibrils, also alter the shape and transparency of the cornea \[[@r10],[@r11]\]. A knockout mouse model has shown that disruption of the genes encoding α1 (*COL8A1*) and α2 chains (*COL8A2*) of type VIII collagen leads to structural changes similar to the clinical presentation of keratoglobus \[[@r12]\]. KC has not been associated with mutations in type VIII collagen genes \[[@r13]\], although a relation between *COL8A2* mutations and dystrophic corneal disorders has previously been reported \[[@r14],[@r15]\]. Results from imunohistochemistry, in situ hybridization, and expression arrays show that several other types of collagen are differentially expressed and have an active role in wound healing processes. Collagen molecules that are differentially expressed in keratoconus corneas are types XII, XIII, XVIII, and XV, but there are no known relations between mutations and expression levels for those genes \[[@r16],[@r17]\]. Upregulation of collagen type XV and downregulation of collagen type IV in KC corneas, observed by Bochert et al. \[[@r18]\] and Stachs et al. \[[@r19]\], showed the putative role of those types of collagen in KC. Types XIII, XV, and XVIII collagen were found to be expressed in basal corneal cells and may have a role in the adhesion of the corneal epithelial cells to each other and to the underlying basement membrane \[[@r16],[@r19]\].

Type IV collagen is found only in basement membranes where it is the major structural component. Mariyama et al. \[[@r20]\] mapped the collagen type IV, alpha-3 (*COL4A3*) and collagen type IV, alpha-4 (*COL4A4*) genes to the same region, 2q35-q37, but on opposite strands and transcribed in opposite directions \[[@r21]\]. The *COL4A3* gene spans 250 kb and consists of 51 exons; the *COL4A4* gene is shorter, spanning 113 kb and consisting of 48 exons \[[@r20],[@r22]\]. *COL4A3* and *COL4A4* are two of six α chains that form heterotrimeric type IV collagen molecules \[[@r20],[@r23],[@r24]\]. Type IV collagen is expressed in corneas and implicated in Goodpasture and Alport syndromes, which are often accompanied by eye abnormalities, but their involvement in eye disorders is still unknown \[[@r22],[@r24]-[@r26]\]. *COL4A3* has already been implicated in the pathogenesis of polymorphous corneal dystrophy-3 \[[@r27],[@r28]\], and both genes are reported to be differentially expressed in keratoconus corneas \[[@r18],[@r19]\]. Results from the study published by Stachs et al., favored collagen type IV as a candidate gene in keratoconus pathogenesis \[[@r19]\]. Because a change in the expression levels of collagen type IV α-3 and α-4 chains were observed in corneas affected by KC, we investigated whether there are alterations in *COL4A3* and *COL4A4* related to KC patients.

Methods
=======

Patients
--------

The genetic study included 104 unrelated patients with KC and 157 healthy blood donors as a control. After examination of the patients (clinical examination, electronic refractometry, and keratometry) and precise personal anamnesis, an unrelated cohort of patients diagnosed with KC was selected for this study. We excluded patients with other ocular diseases that could influence the interpretation of the results: blepharoconjunctivitis, keratitis, opacifications of the lens, changes of the macula, and cup/disc ratio  (C/D) of the optic nerve of 0.3 or more. One hundred and four patients, 65 males and 39 females, were included in this study after informed consent had been obtained and after determination of the diagnostic and other criteria. All the patients included in the study had no other diagnosed disease. The patients' ages were from 20 to 67 years (mean±standard deviation \[SD\] 39.1±8.2 years). For the control population we used peripheral blood taken from 157 blood donors collected at the Blood Transfusion Centre of Slovenia (57 women, 100 men; mean age ± SD 37.2±10.2 years). Blood samples from patients with KC and from healthy Slovenian blood donors were in the form of anticoagulated blood. Blood from KC patients and controls was obtained from the median cubital vein, on the anterior forearm in 3 ml vacuum blood collection tubes with EDTA K3 (Laboratorijska tehnika). Blood was stored in collection tubes at -20 °C until the DNA was isolated. The control group was selected on the basis of age, nationality, and gender comparable with the KC patients. There were no blood relations among individuals in the control group or between individuals in the control group and individuals in the KC group, and control individuals had not been diagnosed with KC. The National Medical Ethics Committee of the Republic of Slovenia approved the study.

DNA extraction and mutational screening
---------------------------------------

Genomic DNA was isolated from peripheral blood lymphocytes by salt precipitation. After the blood samples were thawed, saline-sodium citrate buffer (Merck) was added, mixed on Vibromix (Tehtnica), and the samples centrifuged (12,000 rpm for one minute, centrifuge 5415R; Eppendorf). The top portion of the supernatant was discarded and saline-sodium citrate buffer (Merck) was added, mixed, and again mixture centrifuged under same conditions. Then was supernatant discarded and pellet re-suspended in a solution of sodium dodecyl sulfate detergent (10 % SDS; Sigma-Aldrich) and 5 µl of proteinase K (20 mg/ml H~2~O; Sigma-Aldrich). The mixture was incubated at 55 °C for 1 h (Thermomixer comfort; Eppendorf). After incubation was DNA treated with a phenol/chloroform/isoamyl alcohol solution in ratio 25:24:1 (Sigma-Aldrich).  After centrifugation (12,000 rpm for 1 min, centrifuge 5415R; Eppendorf) was the aqueous layer removed to a new micro centrifuge tube (Costar) and two consecutive DNA ethanol precipitations followed; first one with 100 % and second one with 80 % ethanol (Merck). DNA was re-suspended in 10:1 Tris-EDTA buffer (Sigma-Aldrich) between both precipitations. After the second precipitation the pellets were dried at room temperature followed by addition of 10:1 Tris-EDTA buffer (Sigma-Aldrich). The mixture of DNA and Tris-EDTA buffer (Sigma-Aldrich) was re-suspended with mixing and incubation at 55 °C overnight (Thermomixer comfort; Eppendorf). Amplifications of *COL4A3* and *COL4A4* were performed by PCR. For the PCR reaction we used the primers (Operon) previously described by Heidet et al. \[[@r29]\] (*COL4A3*; [Table 1](#t1){ref-type="table"}) and Boye et al. \[[@r22]\] (*COL4A4*; [Table 2](#t2){ref-type="table"}).

###### Oligonucleotide primers and PCR temperatures used for single-stranded conformational analysis and sequencing of the *COL4A3* gene \[[@r29]\].

  ***COL4A3***   **Sense primer (5\'→3\')**   **Antisense primer (5\'→3\')**   **Length (bp)**   **Annealing temperature (°C)**
  -------------- ---------------------------- -------------------------------- ----------------- --------------------------------
  EX 1           CGGACTCGCCCAGGCTCTGA         GACGCGTGGAGGAGGGATG              176               62
  EX 2           AACAAAACCCTTTCTCTT           AAGCAGTATTAGGGTTTGTT             113               49
  EX 3           TGTGTGTTTCTCACCTCGT          GATTTTCCAAGCTTGCAG               151               54
  EX 4           TTTCTTTTTTCACTTGAATCT        ACGATCAGGGTGGACTG                99                50
  EX 5           CCCCCTCCTTTTTCCTATGT         TTTCTAGCTACGGATTTTTC             102               45
  EX 6           CCTCATTGAGACTTGTTCT          TCATCTTCTGTGTGAAAAGT             116               42
  EX 7           AATAATAAGAAACTTTGTATGT       GGGAATTAGGCATGCAAA               106               49
  EX 8           GTTGTTCATAGGTTGCTTTT         TCAGTGACAGCATTCCAC               83                46
  EX 9           GATGTTTGATGAACTTCTTC         ATAGGGACCTTCTCTGAA               134               52
  EX 10          TACTCTTATTCTTCTCTCAA         CTGTAGCAAGGATGACT                117               49
  EX 11          GTGATTTTCATTTGTGGATT         AGCTGTTACATCATATGAACT            93                48
  EX 12          AATAATTTGGTTTTGTGTT          CCTGCTAATAAAACATAGTA             100               44
  EX 13          ACTCCTGAGTGTTTTTGT           TAATCATAAAATCGCAGA               126               49
  EX 14          TTGTAACAATGTTGAACTGT         ATGGGGACAATATAACTTTA             124               50
  EX 15          ATAAAATTTGACATGGCTCT         GACTAATCAAAACTGCACAT             133               49
  EX 16          TTTCATGTTTTTGATTTGTT         TGACATTTTTACTACCTCCA             116               46
  EX 17          GACCCATTTCTTTTTGTTCT         AAAATAGGCTATTAGGGAGA             110               48
  EX 18          CACAATTTGTAAATGTCTT          GATATTGTCTTTAATCACAC             94                46
  EX 19          TCTGTATTTGTTTCTTTCTC         AAATGCTTTAGGAAGAAAT              141               52
  EX 20          TTATATCTTTCTAAGCCATT         CCTTTGTAATAGCATTTCTA             125               47
  EX 21          TCTCCATTGTGCAATTTTTA         CTAAGCTGTGAGGAGGGTTT             367               53
  EX 22          ATTGTCTTTGGTGCTGTAT          GGCTTATCCTAATACAACAT             156               49
  EX 23          AAGTAATGCTAGTATGCTCTC        TGTGCTTGCAAAAACACT               162               49
  EX 24          TAGTTAATAATTCGTTGA           AAGATTTAAAAACATGAA               121               44
  EX 25          ACAGATTCATTTGTGTACTA         GAGGGTAAAGTTGCTAAATA             234               54
  EX 26          ATTCAAACACATTCCTGT           GGACTGGAAAGAAAACTAA              219               51
  EX 27          ATCTTATGACCACAAATTTC         CAGATTTGGCAGAGGATA               142               54
  EX 28          AGATGCATATGTGTATTTGT         CTTCTAAATATCCACAACAA             182               44
  EX 29          CTAATCCTACAACAATGTTT         TTCTGTGATAGCTTGAATTT             164               47
  EX 30          ATAGTAATAACACAATTTCT         GAGAAAAGTAATGACACT               209               45
  EX 31          CCTGGGTATATACTTGTGCT         ATGTCTCCTGCCCTTCTGG              191               52
  EX 32          GGAAAGCATTTGTGGGTTA          ACAGAGCCACCTTAAGAAGA             276               52
  EX 33          TGCTTTGTGTTAATTTGTTT         TCCTGCTATTTAGAAAGACA             149               52
  EX 34          AAGGACCTGATGTTGTTACT         TCTGATGTCCTGATTCCA               202               52
  EX 35          TTCTTGTTAATACCTGGTTT         TGATATTTTTCTATTTGAGA             160               49
  EX 36          CAGGGCAATAACTACTTA           GCTCATAACAGGACCTTA               146               50
  EX 37          TACTCTATGTTTTCCCCCTA         TCCACCACTAAAATGTAAAT             206               52
  EX 38          TATGAGAATTTTAAAGGTAT         TCCAGCTTTTAGAATTGTAA             195               48
  EX 39          GGTGATCTTTTTTCTTCCTT         CCCACATGAAAAGGAAAAAG             160               50
  EX 40          GGGGTTTTGGGTTTTTTT           ACGGATCAAAGATAATGAGCA            156               52
  EX 41          CAATTATTAACATGCCAAGA         TACATTAGGACAGGGAAGAA             112               50
  EX 42          AAAGAAACTTATTAAGCCTT         TTGTTATTTTATGCTGTTTA             253               52
  EX 43          ATACTGACAGACTTTTCAT          TAATAATGAGTCAAAATAAT             191               50
  EX 44          GTTTTGCTCCCTTTATTTGA         ATATAAAGAGCAATGCACAA             129               51
  EX 45          GGAAACCCATTGATCTAAGT         ACCTTTCTTCATTGACAGCA             164               51
  EX 46          TGAGGCCATCATCTTCTTCT         TCCTAGTGATCCAAGTCAAT             199               50
  EX 47          CCACCTTACTTTTCATCCTAT        ACTTCTTCGGTGAGGAAAC              190               59
  EX 48          CTTTGAAAAAACGAGTTTAAG        TTACAATCTGCATGTGGAA              324               61
  EX 49          CTAGTAACGATGCTGAAAATAAC      TCACTTGGTCCCATTGTAA              284               54
  EX 50          TTCCCTTGTAATGGAATGAAA        CACATTTTACCCAGCACAAT             271               52
  EX 51          AACCCCAATGGACAGAGTGTT        TGAATAGTTCTGCAATTGAGT            272               63
  EX 52          CAGCAAAAATTCCCTTTTATG        TGTTCTTTAGGATGAAAAAT             190               47

In the table, Length represents length of the PCR product in base pairs (bp) and Annealing temp represents the annealing temperature of the primers used for PCR reactions.

###### Oligonucleotide primers and PCR temperatures used for single-stranded conformational analysis and sequencing of the *COL4A4* gene \[[@r22]\].

  ***COL4A4***   **Sense primer (5\'→3\')**   **Antisense primer (5\'→3\')**   **Length (bp)**   **Annealing temperature (°C)**
  -------------- ---------------------------- -------------------------------- ----------------- --------------------------------
  EX 2           TCTGGAAGAGAAGACTGGCA         AAGCAGGCAATCACACTGA              153               54
  EX 3           TGTTTAAATTAATCTGCGTT         GCAACCAGAGCTAGTG                 105               48
  EX 4           CGATGAGTACTGGTATACTA         ATGCTGCCCATGTTGGTCTT             152               50
  EX 5           ACCCCCATTTCTTTTTAATC         GGTGAGTCTTTCATGTGAAT             208               54
  EX 6           TCTCTTTGTTTTATTTTCTG         GATGAGTACTTCTGCCTTTT             127               47
  EX 7           TTTCGCAAAAATGCTTCACT         CCACAGGGCCTGTTCACTTA             211               60
  EX 8           TACTGAAATGGTAATACGCT         CATGGGCTTACCTATTTGGA             184               48
  EX 9           TGTGTGGACTTAAAGCGATG         TAGAGCCTGCTCAGGAGACT             96                53
  EX 10          TTGGGTAACAGATGCACTGA         AAGGGATCACATCAGCAGTG             129               55
  EX 11          TTGTGTTTTTTTCTCCCTTG         TTTCATTGTTCAGGGCTCTA             109               50
  EX 12          AGCCAGAAGTCTTAATTGCT         TCACCATTTGCTCCTCAGAG             156               54
  EX 13          GGGTGGAAACCTTCAAAACA         TACTTTCCAAGGTGACATAT             179               50
  EX 14          GGAGATGGAATTCAGTATGT         AAAGACCATGAGAAATAACA             197               53
  EX 15          CCCCTCTAAATGTTGTCATC         TTTGAGCTTGTGGGACTACT             180               54
  EX 16          AATGATGCACTGAGCTGGTT         GCACGCAACAGTACAACTTC             200               53
  EX 17          ATTTGTCACCCCGTCACTTT         GAATGATTCCTGGCAATACT             201               50
  EX 18          CCAGGCAACATGAGTAAAAT         TGGAGGAACTGAATAGGAAC             155               50
  EX 19          TGCACATACCATTTGTTTAT         CCAGGGCACATCAGGGCATC             175               50
  EX 20          TTCTTCTACAGAGACGTTT          TGCTAATGGATATGAATAAG             259               52
  EX 21          TATAGAAGACAGTCAGAAAA         TAGAAATTCTACCTTTGGTG             181               50
  EX 22          AAATATGACAAATCTGCCAT         GGAAAGATGACTGGTAAGAG             227               50
  EX 23          TGATCCATCACAATTAACCT         CAGGGAGTTAAGTGATTGAT             149               53
  EX 24          ACTTTACCCTCTGCTGATAA         GGGAAATAGTTGTTTGTATG             223               50
  EX 25          GACATTCAGTGGTTGGTAAT         TAAACACTTGTACCCCAAAG             280               60
  EX 26          TCAGTTATGTGAATGCCGCT         TGGGAAGTATATAAGACAGT             147               50
  EX 27          TGAGTCTGTGTTTTGTTTTT         AAAAAAAAAAACCTCAC                210               52
  EX 28          ATTGGTTCTATACTTGCACA         TCTATGCACCAAAAGGACAG             309               54
  EX 29          TGGGCCATCTGTATAGTTTT         TAATAGTAAGTAGGGTAAGC             269               57
  EX 30          GCCTTCACACACTGTGGTCA         ATGGGAGGACATCATGGAAA             240               55
  EX 31          TCCTAAAACTTTATGCTCTC         TCAAATACCAGAAACAAATG             221               53
  EX 32          CCTGTTCATTTTGTTCTTGC         TGTCAACTTATTTGATATGG             187               57
  EX 33          TTTCAGCAGAGACCTGTAAC         AAGAACAGAAAGGTTTTATT             271               52
  EX 34          GTTGTGCATGTGCCATTTGT         GATGGCTTCTGTATCTCC               154               50
  EX 35          TGAGACCAAATTAAATTGTC         TCATTGCCAGCTAGAAGTAA             210               52
  EX 36          CAAACGGCAACTCTGATGTT         AGTGCTCAGGAAGTCTCCAG             183               55
  EX 37          TATCTGGCCATCTGCAAAAC         TTGTGGGATGGGCTTCATTT             173               55
  EX 38          GCGTTTGTGGCTAGAGTGAG         GAACCATGGACTGAAGCTCAG            190               57
  EX 39          AGGCACTATAACAGGGACAAGA       GGAGTAACGTAAACCTTCCA             256               60
  EX 40          ACCTTCCAAATGCAATGAGG         CATCCTTTGTCATGATTCTCTC           184               53
  EX 41          TTTTTGTCTCTTCTCTGTGG         AGTTATTCACATATTACTTA             218               48
  EX 42          GCCCTCATTTTTATGTTTTG         GTTGGAAGCTCACCTGGAAG             153               54
  EX 43          GACTGGCCTCGTTTG              TTAATATCCTTACAGCACCC             180               50
  EX 44          ATTACACAAGCGGTGATTCC         TGGCTCCTTCTGGTCCTCTC             118               56
  EX 45          CACCAGCATCATAAACTT           AGGTTTACAGTGTCAGAGAA             186               53
  EX 46          AGTGCCAGAACAGAGGTGCT         GGAGATGGGCGATCCTGTA              297               57
  EX 47          ACACCAGCTGTCTCTTCTTC         TGAATGAGCCAGGGTTT                353               57
  EX 48          GTGTGTGTCTGAGCCCTAAT         TGGTGAATTTCGCATTCT               322               50

In the table, Length represents length of the PCR product in base pairs (bp) and Annealing temp represents the annealing temperature of the primers used for PCR reactions.

Screening for changes in PCR products was performed with single-stranded conformation analysis (SSCA) for each PCR fragment of a given set of samples from patients and healthy blood donors. Large glass plates (35×40 cm) were used to obtain maximum sensitivity. The shorter plate was coated with Repel-Silane (Merck). The longer plate was coated with Bind-Silane (20 ml of g-methacryloxypropyltrimethoxysilane, 5 ml of bi-distilled H~2~O, 5 ml of 100 % ethanol; Merck), then warmed to 50 °C for about 30 min and cooled to room temperature. A 3 ml portion of PCR product was mixed with 10 ml of loading buffer (95% formamide, 5 mM NaOH, 0.1% bromophenol blue, and 0.1% xylene cyanol, Sigma-Aldrich). Samples were heated to 95 °C for 2 min and then cooled in ice water. Each PCR product mixed with loading buffer was loaded onto polyacrylamide gels (35×40×0.04 cm). Combs with 96 teeth were used for loading samples and 10% acrylamide gels (Merck) with 2.6% bis-acrylamide (Merck) to analyze multiple exons at once. Gels were run at 4 °C in 1× TBE (50mM Tris-borate, pH 8.3, 4 mM ethylenediaminetetraacetic acid; Merck). For DNA visualization, we used the optimized method of Heukeshoven and Dernick \[[@r30]\] with most phases at 55°C. Silver staining (Merck) was performed on thin gels (0.4 mm) fixed on the larger glass plate. Samples with different migration shifts were chosen for sequencing, which was done with a BigDye Terminator Ready Reaction Mix (Applied Biosystems). Sequences were purified, dissolved, and analyzed on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems; [Figure 1](#f1){ref-type="fig"} and [Figure 2](#f2){ref-type="fig"}).

![**A**: Three different PCR--single stranded conformational analysis patterns on one gel, representing *COL4A3* exons 17, 48, and 49. PCR fragments were loaded in succession from shortest to longest PCR fragment at 30-min intervals. Exons 48 and 49 did not show any differences in elution shifts; in exon 17, the different patterns were subsequently sequenced. **B**: Partial sequence of exon 17 with heterozygous substitution D326Y (976GT). **C**: Partial sequence of exon 17 with homozygous substitution 326Y (976TT). K1 to K4 marked patterns are patterns of three exons (17, 48, and 49) of *COL4A3* from keratoconus patients, multiplied by PCR and analysed with SSCA. C1 to C3 marked patterns are patterns of three exons (17, 48, and 49) of *COL4A3* from controls multiplied by PCR and analysed with SSCA. \'1/1\', \'2/2\' denote different genotypes at position 976 (1/2 being GT and 2/2 being TT) in *COL4A3*. GG genotypes, being  \'1/1' genotypes, are unmarked. Single stranded DNA (ssDNA) and double stranded DNA (dsDNA) patterns are marked on the side of the SSCA gel.](mv-v15-2848-f1){#f1}

![**A**: Three different PCR--single stranded conformational analysis patterns on one gel, representing *COL4A4* exons 9, 10, and 42. PCR fragments were loaded in succession from shortest to longest PCR fragment at 30-min intervals. Exons 9 and 10 did not show any differences in elution shifts; in exon 42, different patterns were subsequently sequenced. **B**: Partial sequence of exon 42, made with reverse primer, showing homozygous substitution 1327M (3797AA). The position marked on reverse sequence is 3797TT. **C**: Partial sequence of exon 42, made with reverse primer, showing homozygous substitution 1327V (3797GG). The position marked on reverse sequence is 3797CC. \'1/1\','1/2' and \'2/2\' denote different genotypes at position 1327 in *COL4A4*. Single stranded DNA (ssDNA) and double stranded DNA (dsDNA) patterns are marked on the side of the SSCA gel.](mv-v15-2848-f2){#f2}

Deviations of the Hardy-Weinberg equilibrium
--------------------------------------------

Deviations of the Hardy-Weinberg (H-W) equilibrium were calculated with the χ^2^ [online test](http://www.husdyr.kvl.dk/htm/kc/popgen/genetik/applets/kitest.htm) with 1 degree of freedom (DF=1) for each polymorphism found in KC patients and control groups. By the use of a χ^2^ table, with DF=1, the limits for maintaining a null hypothesis (that the observed data has Hardy-Weinberg proportions) were obtained. If the result equaled or was less than 0.05 (5% limits), we concluded that there was no statistical deviation from the Hardy-Weinberg equilibrium in our data ([Table 3](#t3){ref-type="table"}).

###### Data about observed polymorphisms in keratoconus patients and controls with calculated deviation from Hardy-Weinberg equilibrium.

  **Polymorphism**   **Exon**   **dbSNP ref ID**   **Hardy-Weinberg CHI (p-value)**   
  ------------------ ---------- ------------------ ---------------------------------- ---------------------
  ***COL4A3***                                                                        
  G43R               2          rs13424243         0.2127 (p\>0.2)                    0.2928 (p\>0.2)
  P141L              7          rs10178458         2.1005 (p\<0.2)                    18.333 (p\<0.0001)
  E162G              9          rs6436669          1.6271 (p\>0.2)                    0.9575 (p\>0.2)
  D326Y              17         rs55703767         3.6385 (p\<0.1)                    11.6848 (p\<0.001)
  H451R              22         rs11677877         0.6282 (p\>0.2)                    0.8912 (p\>0.2)
  G484G              23         rs34019152         0.2127 (p\>0.2)                    0.4525 (p\>0.2)
  P574L              25         rs28381984         4.7767 (p\<0.05)                   0.8502 (p\>0.2)
  G895G              33         ref\*              0.2376 (p\>0.2)                    5.8157 (p\<0.02)
  ***COL4A4***                                                                        
  P482S              21         rs2229814          0.5769 (p\>0.2)                    30.0822 (p\<0.0001)
  G545A              23         rs1800516          0.1261 (p\>0.2)                    0.2928 (p\>0.2)
  G789G              28         rs56247709         5.0335 (p\<0.025)                  0.2478 (p\>0.2)
  M1327V             42         rs2229813          12.1981 (p\<0.001)                 9.1888 (p\<0.01)
  V1516V             47         rs2228555          0.6683 (p\>0.2)                    8.5342 (p\<0.01)
  F1644F             48         rs2228557          0.4009 (p\>0.2)                    1.3937 (p\>0.2)

[dbSNP](http://www.ncbi.nlm.nih.gov/projects/SNP/) ref ID: identity numbers for observed variants; ref\*: polymorphism is not listed in dbSNP, but was reported by Wang et al. \[[@r34]\]. Hardy-Weinberg CHI (p-value): calculated chi values according to our data for cases and controls separately, and deviation between observed and expected numbers. When p-value equals or is less than 0.05 (5%) limit, then there is no statistical deviation from the Hardy-Weinberg equilibrium.

Associations between allele and genotype frequencies
----------------------------------------------------

The magnitudes and directions of associations between the polymorphisms found and KC patients were determined using Fisher's exact test with a two-sided p value. Fisher's exact test was chosen because it is based on exact probabilities from a specific distribution and is the preferred tool over the χ^2^ when comparing small data samples and a large sample approximation would be inappropriate. A two-sided p value was calculated to determine the significance of the relationship, and a value of p\<0.05 was considered statistically significant. Significant relationships for each allele or genotype group between KC patients and the control group are summarized as odds ratio (OR) and relative risk (RR; [Table 4](#t4){ref-type="table"}).

###### Allele frequencies and their significances in *COL4A3* and *COL4A4* polymorphisms between keratoconus patients and control population.

  ***COL4A3* polymorphism**   **Allele**   **Cases (n=208)**   **Controls (n=314)**   **p-value**   **OR**   **RR**
  --------------------------- ------------ ------------------- ---------------------- ------------- -------- --------
  G43R                        127G         199                 301                                            
                              127C         9                   13                     1.0000                  
  P141L                       422C         172                 261                                            
                              422T         36                  53                     0.9059                  
  E162G                       485A         174                 262                                            
                              485G         34                  52                     1.0000                  
  D326Y                       976G         199                 187                                            
                              976T         9                   127                    \<0.0001      15.017   7.790
  H451R                       1352A        193                 292                                            
                              1352G        15                  22                     1.0000                  
  G484G                       1452G        199                 298                                            
                              1452A        9                   16                     0.8349                  
  P574L                       1721C        118                 166                                            
                              1721T        90                  148                    0.4195                  
  G895G                       2685A        137                 227                                            
                              2685C        71                  87                     0.1208                  
  ***COL4A4* polymorphism**   **Allele**   **Cases (n=208)**   **Controls (n=314)**   **p-value**   **OR**   **RR**
  P482S                       1444C        117                 182                                            
                              1444T        91                  132                    0.7183                  
  G545A                       1634G        201                 301                                            
                              1634C        7                   13                     0.8168                  
  G789G                       2367G        200                 302                                            
                              2367A        8                   12                     1.0000                  
  M1327V                      3979A        74                  182                                            
                              3979G        134                 132                    \<0.0001      0.4005   0.5738
  V1516V                      4548A        119                 184                                            
                              4548G        89                  130                    0.7861                  
  F1644F                      4932C        136                 163                                            
                              4932T        72                  151                    0.0028        1.750    1.409

Cases: number of alleles found in keratoconus patients, Controls: number of alleles found in healthy blood donor population, n: number of all alleles, p-value: two sided p-value calculated with Fisher's exact test for determining the significance between differences in alleles found in keratoconus patients and controls for each polymorphism, OR: odds ratio, RR: relative risk. OR and RR are shown only for polymorphisms for which allele differences are significant (p-value less than 0.05).

The significance of genotype frequencies for each polymorphism found in the two-tested groups (patients and controls) was tested in two models, dominant and recessive. A dominant model was constructed on the basis of a presumption that at least one allele would be changed. We therefore combined the number of heterozygous genotypes with the number of homozygous genotypes for each polymorphism genotype and analyzed whether the representation of genotypes was significantly different between cases and controls for each polymorphism ([Table 5](#t5){ref-type="table"}). A recessive model was constructed on the basis of a presumption that both alleles would be changed. Therefore the number of homozygous genotypes against combined heterozygous and homozygous genotypes for another allele were compared for each polymorphism and whether the representation of genotypes was significantly different between cases and controls for each polymorphism was analyzed ([Table 5](#t5){ref-type="table"}). An additive model was constructed to test the significances between KC patients and the control group for all genotypes in detected polymorphisms ([Table 6](#t6){ref-type="table"}). For statistics we used the Fisher's exact test, and when the two-sided value was less than 0.05, the results were summarized as an OR and RR. All statistical analyses were performed using SPSS ver.14 (SPSS Inc.).

###### Genotype representation and associations under dominant and recessive model between keratoconus patients and controls.

  ***COL4A3* polymorphism**   **Genotype**   **Cases (n=104)**   **Controls (n=157)**   **Dominant model**   **Recessive model**                                            
  --------------------------- -------------- ------------------- ---------------------- -------------------- --------------------- ------------ -------------- ------------ ------------
  G43R                        127GG          95                  144                    NC                   NC                    NC           1.0000                       
                              127CC          0                   0                      1.0000                                                  NC             NC           NC
                              127GC          9                   13                                                                                                          
  P141L                       422CC          69                  116                    **0.0177**           **8.524**             **5.399**    0.2115                       
                              422TT          1                   12                     0.2115                                                  **0.0177**     **0.117**    **0.1852**
                              422CT          34                  29                                                                                                          
  E162G                       485AA          71                  111                    0.2489                                                  0.6821                       
                              485GG          1                   6                      0.6821                                                  0.2489                       
                              485AG          32                  40                                                                                                          
  D326Y                       976GG          96                  66                     **\<0.0001**         **30.645**            **17.013**   **\<0.0001**   **16.545**   **7.333**
                              976TT          1                   36                     **\<0.0001**         **0.060**             **0.136**    **\<0.0001**   **0.033**    **0.058**
                              976GT          7                   55                                                                                                          
  H451R                       1352AA         89                  135                    NC                   NC                    NC           1.0000                       
                              1352GG         0                   0                      1.0000                                                  NC             NC           NC
                              1352AG         15                  22                                                                                                          
  G484G                       1452GG         95                  141                    NC                   NC                    NC           0.8306                       
                              1452AA         0                   0                      0.8306                                                  NC             NC           NC
                              1452GA         9                   16                                                                                                          
  P574L                       1721CC         28                  41                     0.5039                                                  0.3853                       
                              1721TT         14                  32                     0.3853                                                  0.5039                       
                              1721CT         62                  84                                                                                                          
  G895G                       2685AA         44                  76                     **0.0399**           **0.336**             **0.589**    0.3752                       
                              2685CC         11                  6                      0.3752                                                  **0.0399**     **2.977**    **1.698**
                              2685AC         49                  75                                                                                                          
  ***COL4A4* polymorphism**   **Genotype**   **Cases (n=104)**   **Controls (n=157)**   **Dominant model**   **Recessive model**                                            
  **p-value**                 **OR**         **RR**              **p-value**            **OR**               **RR**                                                         
  P482S                       1444CC         31                  36                     **0.0147**           **0.360**             **0.597**    0.2474                       
                              1444TT         18                  11                     0.2474                                                  **0.0147**     **2.788**    **1.674**
                              1444CT         55                  110                                                                                                         
  G545A                       1634GG         97                  144                    NC                   NC                    NC           0.8130                       
                              1634CC         0                   0                      0.8130                                                  NC             NC           NC
                              1634GC         7                   13                                                                                                          
  G789G                       2367AA         97                  145                    0.3985                                                  1.0000                       
                              2367TT         1                   0                      1.0000                                                  0.3985                       
                              2367AT         6                   12                                                                                                          
  M1327V                      3979AA         5                   62                     0.0897                                                  **\<0.0001**   **0.077**    **0.146**
                              3979GG         35                  37                     **\<0.0001**         **12.922**            **6.838**    0.0897                       
                              3979AG         64                  58                                                                                                          
  V1516V                      4548AA         32                  53                     **0.0362**           **1.993**             **1.561**    0.6861                       
                              4548GG         17                  44                     0.6861                                                  **4**          **0.502**    **0.641**
                              4548AG         55                  60                                                                                                          
  F1644F                      4932CC         43                  46                     **0.0038**           **2.890**             **2.053**    **0.0469**     **1.701**    **1.362**
                              4932TT         11                  40                     **0.0469**           **0.588**             **0.734**    **0.0038**     **0.346**    **0.487**
                              4932CT         50                  71                                                                                                          

Significant differences are shown in bold. Cases: keratoconus patients, Controls: healthy blood donors, n: number of individuals, NC- not calculated, Genotype: Genotypes found representing each polymorphism in cases and controls. Fisher's exact test was used for statistics. Differences between genotypes are significant when two-sided p-value (p-value) is less than 0.05. OR: Odds ratio, RR: relative risk. OR and RR are shown only for genotypes with significant differences (p-value less than 0.05). Dominant model column shows Fisher's test results calculated from the sum of the number of individuals with homozygous and heterozygous genotypes compared to the number of individuals with another homozygous genotype for each polymorphism. Recessive model column shows Fisher's test results obtained by comparing the number of individuals with homozygous genotype against the sum of individuals with another homozygous or heterozygous genotype for each polymorphism.

###### Genotype representation and associations under additive model between keratoconus patients and controls.

  ***COL4A3* polymorphism**   **Genotype**   **Genotype comparison**   **Additive model**                
  --------------------------- -------------- ------------------------- -------------------- ------------ ------------
  G43R                        127GG          GG versus CC              NC                   NC           NC
                              127CC          GC versus GG              1.0000                             
                              127GC          GC versus CC              NC                   NC           NC
  P141L                       422CC          **CC versus TT**          **0.0325**           **7.138**    **4.849**
                              422TT          **CT versus CC**          **0.0262**           **1.971**    **1.447**
                              422CT          **CT versus TT**          **0.0022**           **14.069**   **7.016**
  E162G                       485AA          AA versus GG              0.2550                             
                              485GG          AG versus AA              0.4790                             
                              485AG          AG versus GG              0.2289                             
  D326Y                       976GG          **GG versus TT**          **\<0.0001**         **52.364**   **21.926**
                              976TT          **GT versus GG**          **\<0.0001**         **0.0875**   **0.1905**
                              976GT          GT versus TT              0.2520                             
  H451R                       1352AA         AA versus GG              NC                   NC           NC
                              1352GG         AG versus AA              1.0000                             
                              1352AG         AG versus GG              NC                   NC           NC
  G484G                       1452GG         GG versus AA              NC                   NC           NC
                              1452AA         GA versus GG              0.8306                             
                              1452GA         GA versus AA              NC                   NC           NC
  P574L                       1721CC         CC versus TT              0.3248                             
                              1721TT         CT versus CC              0.8825                             
                              1721CT         CT versus TT              0.1686                             
  G895G                       2685AA         **AA versus CC**          **0.0352**           **0.3158**   **0.5667**
                              2685CC         AC versus AA              0.6933                             
                              2685AC         AC versus CC              0.0667                             
  ***COL4A4* polymorphism**   **Genotype**   **Genotype comparison**   **Additive model**                
  **p-value**                 **OR**         **RR**                                                      
  P482S                       1444CC         CC versus TT              0.1857                             
                              1444TT         CT versus CC              0.0726                             
                              1444CT         **CT versus TT**          **0.0061**           **0.3056**   **0.5370**
  G545A                       1634GG         GG versus CC              NC                   NC           NC
                              1634CC         GC versus GG              0.8130                             
                              1634GC         GC versus CC              NC                   NC           NC
  G789G                       2367AA         AA versus TT              0.4033                             
                              2367TT         AT versus AA              0.6270                             
                              2367AT         AT versus TT              0.3684                             
  M1327V                      3979AA         **AA versus GG**          **\<0.0001**         **0.0853**   **0.1535**
                              3979GG         **AG versus AA**          **\<0.0001**         **13.683**   **7.030**
                              3979AG         AG versus GG              0.6567                             
  V1516V                      4548AA         AA versus GG              0.2864                             
                              4548GG         AG versus AA              0.1940                             
                              4548AG         **AG versus GG**          **0.0153**           **2.373**    **1.716**
  F1644F                      4932CC         **CC versus TT**          **0.0021**           **3.399**    **2.240**
                              4932TT         CT versus CC              0.3283                             
                              4932CT         **CT versus TT**          **0.0148**           **2.561**    **1.916**

Significant differences are shown in bold. Statistics were based on genotype representation shown in [Table 5](#t5){ref-type="table"} (104 keratoconus patients and 157 controls). NC- not calculated, Genotype: Genotypes found representing each polymorphism in cases and controls. Fisher's exact test was used for statistics. Genotype comparison: genotypes compared against each other. Differences between genotypes are significant when two-sided p-value (p-value) is less than 0.05. OR: Odds ratio, RR: relative risk. OR and RR are shown only for genotypes with significant differences (p-value less than 0.05).

SIFT and PolyPhen predictions for polymorphisms causing amino acid substitution
-------------------------------------------------------------------------------

The potential impact of polymorphisms causing amino acid substitution was assessed with two analytic tools: SIFT and PolyPhen. [SIFT](http://sift.jcvi.org/www/SIFT_chr_coords_submit.html) is a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution in a protein will have a phenotypic effect. SIFT is based on the premise that protein evolution is correlated with protein function. Positions important for function should be conserved in the alignment of the protein family, whereas unimportant positions should appear diverse in the alignment. The SIFT tool calculates a score for the amino acid substitution, and a score lower than 0.05 is considered potentially damaging ([Table 7](#t7){ref-type="table"}). [PolyPhen](http://genetics.bwh.harvard.edu/pph/) (Brigham and Women\'s Hospital, Harvard Medical School) is a tool for predicting the possible impact of an amino acid substitution on the structure and function of a human protein. This prediction is based on straightforward empirical rules, which are applied to the sequence, phylogenetic, and structural information characterizing the substitution. The PolyPhen tool uses Position-Specific Independent Counts software to calculate profile scores obtained from the likelihood of a given amino acid occurring at a position of interest compared to background frequencies (the likelihood of this amino acid occurring at any position; [Table 7](#t7){ref-type="table"}).

###### Prediction of effect of substitution polymorphisms found in KC and healthy population.

  ***COL4A3* polymorphism**   **PolyPhen prediction (score)**   **SIFT prediction (score)**
  --------------------------- --------------------------------- -----------------------------
  G43R                        possibly damaging (1.800)         not tolerated (0.00)
  P141L                       probably damaging (2.250)         tolerated (0.40)
  E162G                       benign(0.024)                     tolerated (0.64)
  D326Y                       probably damaging (2.025)         tolerated (0.08)
  H451R                       benign (1.426)                    tolerated (0.54)
  P574L                       probably damaging (2.250)         tolerated (0.19)
  ***COL4A4* polymorphism**   **PolyPhen prediction (score)**   **SIFT prediction (score)**
  P482S                       benign (1.125)                    tolerated (0.71)
  G545A                       benign (1.350)                    not tolerated (0.01)
  M1327V                      benign(0.017)                     tolerated (0.13)

The [PolyPhen](http://genetics.bwh.harvard.edu/pph/) (Polymorphism Phenotyping) tool predicts the possible impact of an amino acid substitution on the structure and function of a human protein using straightforward physical and comparative considerations. The [SIFT](http://sift.jcvi.org/) (Sorting Intolerant From Tolerant) tool predicts whether an amino acid substitution will affect the protein function; based on sequence homology and the physical properties of amino acids it calculates the potential impact of the amino acid change (score lower than 0.05 is considered potentially damaging).

Results
=======

Mutational analysis
-------------------

Mutational analysis of all exons in *COL4A3* and *COL4A4* genes did not reveal any mutations in KC patients. We detected eight polymorphisms in *COL4A3*, six of them amino substitutions (G43R, P141L, E162G, D326Y, H451R, and P574L), and six polymorphisms in *COL4A4*, three of them amino acid substitutions (P482S, G545A, and M1327V; [Table 3](#t3){ref-type="table"}, [Figure 1](#f1){ref-type="fig"} and [Figure 2](#f2){ref-type="fig"}). All of the polymorphisms were also detected in the healthy population and have previously been described as showen in [Table 3](#t3){ref-type="table"}.

Hardy-Weinberg equilibrium
--------------------------

When analyzing the H-W equilibrium, we discovered that the frequencies of most of the polymorphisms discovered deviate from expected numbers in both KC patients and controls. In the *COL4A3* gene, only three (P141L, D326Y, and G895G) polymorphisms in the control group and two (D326Y and P574L) polymorphisms in the KC patient group had a p value less than the 5% limit, which was the cut-off value for determining no statistical deviation from the H-W equilibrium. In *COL4A4,* the observed frequencies of three polymorphisms (P428S, M1327V, and V1516V) in the control group and two (G789G and M1327V) in the KC patient group did not deviate from the H-W equilibrium ([Table 3](#t3){ref-type="table"}).

Associations between allele and genotype frequencies
----------------------------------------------------

The allele frequency in three polymorphisms was significantly associated with KC patients ([Table 4](#t4){ref-type="table"}). P141L, D326Y, and G895G in *COL4A3* and P482S, M1327V, V1516V, and F1644F in *COL4A4* polymorphisms were associated with KC patients, either as genotypes or alleles, with calculated p values less than 0.05 (Fisher's exact test; [Table 4](#t4){ref-type="table"}, [Table 5](#t5){ref-type="table"}, and [Table 6](#t6){ref-type="table"}). Significantly represented alleles in KC patients are 976G (D326Y, *COL4A3*) with OR= 15.017, 3979G (M1327V, *COL4A4*) with OR= 2.497, and 4932C (F1644F, *COL4A4*) with OR= 1.750 ([Table 4](#t4){ref-type="table"}). When analyzing the representation of genotypes for all the polymorphisms found between KC patients and controls, we discovered that some of the genotypes were significantly represented only in the KC patient group ([Table 4](#t4){ref-type="table"}). The analysis was performed in relation to the representation of mandatory both (recessive) or at least one allele (dominant) being changed.

In terms of the dominant model, genotypes 422CC (OR=8.524) and 976GG (OR=30.645) in *COL4A3* and 3979GG (OR=12.922), 4548AA (OR=1.993), and 4932CC (OR= 2.890) in *COL4A4* are significantly related to KC patients ([Table 5](#t5){ref-type="table"}). Significantly higher represented genotypes with the recessive model are 976GG (OR=16.545) and 2685CC (OR=2.977) in *COL4A3* and 1444TT (OR=2.788) and 4932CC in *COL4A4* (OR=1.701; [Table 5](#t5){ref-type="table"}).

We also discovered through analysis of both models that some of the genotypes were significantly less frequent in KC patients: 976TT and 2685AA in *COL4A3* and 1444CC and 4932 TT in *COL4A4* for the dominant model; 422TT and 976TT in *COL4A3* and 3979AA, 4548GG, and 4932TT in *COL4A4* for the recessive model ([Table 5](#t5){ref-type="table"}). In the additive model, genotypes 422CC, 422TT, 422CT, 976GG, 976TT, and 2685AA in *COL4A3* and 1444CT, 3979AA, 3979GG, 4548AG, 4932CC, and 4932CT in *COL4A4* were significantly different between KC patients and the control group ([Table 6](#t6){ref-type="table"}).

SIFT and PolyPhen predictions
-----------------------------

PolyPhen analysis predicted that G43R, P141L, D326Y, and P574L polymorphisms in the *COL4A3* gene are potentially damaging. All tested missense polymorphisms in *COL4A4* are predicted to be benign. SIFT tool analysis gave a score less than 0.05 for G43R in *COL4A3* and G545A in *COL4A4*. Those substitutions are predicted to affect the protein function and would not be tolerated. All other substitutions are predicted as tolerated ([Table 7](#t7){ref-type="table"}).

Discussion
==========

To our knowledge this is the first report describing the genetic screening of two type IV collagen genes in KC patients. Frequent polymorphisms in affected and healthy populations were found, but no mutations in either of the genes that could be related to KC were discovered. Previous data have revealed that the expression of type IV collagen is deregulated in KC patients and that chromosome locations with genes important in the regulation of collagen synthesis (including type IV collagen) are frequently subjected to aneuploidy and translocation \[[@r18],[@r31]\]. Given the identification of changed amounts of collagen and no affirmative data about relations between mutations in already researched collagen genes and KC, we analyzed the *COL4A3* and *COL4A4* genes, which are deregulated in KC patients, are often subjected to chromosomal aberrations, and could also be responsible for a decrease in collagen types I and III, a feature often detected in the disease \[[@r8],[@r9],[@r11],[@r18],[@r19],[@r31]\].

All of the alterations found in both genes have already been published in other studies. When analyzing whether polymorphisms found were in H-W equilibrium, we discovered that most of them were not. It is difficult to speculate the main reason for this, but some of the probable causes of population differences shown in the study are selection, small population size, population stratification, and genetic drift. It is not rare to find that polymorphisms are in H-W disequilibrium because of the above-mentioned reasons. The control group was selected as described in the Methods section. Considering the small number of some of the alleles found, it is easy to predict that a larger sample size of controls and inclusion of different nationalities and races could help to meet the criteria for H-W equilibrium, but the allele frequencies described in our study are comparable to ones found by Šlajpah et al. \[[@r32]\]. Even though obvious violations to the H-W equilibrium were detected, genotypes and allele representations for some polymorphisms statistically differ between groups and are much more frequent in the KC patients than in the healthy population, which should be taken into consideration when assessing differences between genotypes and phenotypes for a chosen population.

For predicting the effect of substitutions found, we used two different tools, PolyPhen and SIFT, which predict the possible impact on the structure and function of protein substitutions. *COL4A3* G43R, P141L, D326Y, and P574L polymorphisms were predicted to have an effect when analyzed with PolyPhen, but SIFT predicted that only G43R would be damaging. Out of all the substitutions found in *COL4A4*, only G545A was predicted by SIFT to be damaging. Discrepancies between predictions using different tools are expected because the matrices and nature of assessing the damaging effects are based differently. PolyPhen predicts the functional effect of substitutions by determining the level of sequence conservation between homologous genes over evolutionary time, the properties of the exchanged residues, and the proximity of the substitution to predicted putative protein domains and structural features within the protein. SIFT predicts the functional importance of an amino acid substitution based on the alignment of highly similar protein sequences. Predictions rely on whether or not an amino acid at the position of our interest is conserved in the protein family, which can be indicative of its importance to the normal function or structure of the expressed protein. Not all substitutions predicted to affect protein function are involved in disease development and/or progression, especially in the complex diseases, such as KC. Still in the absence of functional data, it is advantageous to use predictive tools to identify substitutions that would more likely affect wild-type protein function; nevertheless differences in results using prediction tools and statistical evaluation of allele/genotype distribution between groups are to be expected.

The allele distributions of three polymorphisms already described in previous studies related to Alport syndrome (D326Y \[[@r29]\] in *COL4A3* and M1327V \[[@r22],[@r33]\] and F1644F \[[@r33]\] in *COL4A4*) were significant for the KC patient cohort. We cannot speculate that these polymorphisms in any way alter the collagen assembly or promote KC disease, although SIFT and PolyPhen predict D326Y to be damaging and the substitution could have an effect on the structure and function of the protein. The other two alleles significant for KC patients were found in the *COL4A4* gene, resulting in one missense and one silent alteration (3979G, M1327V and 4932C, F1644F), although substitution is predicted to be benign and tolerated. When comparing genotypes, we discovered specific genotypes related to KC patients even though the allele distribution was not significantly different. Under different models (dominant, recessive, and additive), we found a significant representation of the following genotypes: 422CC, 422TT, 422CT, and 2685CC in *COL4A3* and 1444TT, 4548AA, and 4548AG in *COL4A4*. The prediction tools used showed the possibility that some of the substitution resulting from these genotypes could be damaging ([Table 7](#t7){ref-type="table"}). In order to conclude whether genotype representations are specific for our population or are in fact disease specific, different populations should be examined and data compared.

In view of the lack of mutations, we could speculate that mutations in collagen type IV (*COL4A3* and *COL4A4* genes) are not involved in KC disease and that other genes and factors are involved in the pathogenesis of this disorder, but functional assay would be required to clarify this speculation. This study established that significant relationships between KC patients and different genotypes in *COL4A3* and *COL4A4* exist, so the significance of the genotypes should be established by further analysis that would involve different populations. There is a possibility that some of the polymorphisms could be related to KC, a feature that could be used in helping the determination of the molecular genetics of the disease.
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